Unlocking CNS Oncology: Innovation, Investment, and What’s Next in Glioblastoma and Beyond

An exclusive KOL-based strategic report to de-risk decisions in one of the most complex areas of oncology.

Purpose-Built for Pharma Executives and Investors

This isn’t a generic market scan. This report is built on a vetted KOL framework developed in collaboration with seasoned industry leaders and senior clinical experts, designed to answer the strategic questions BD, portfolio, innovation, and investor teams actually wrestle with.
You’re not pre-ordering content. You’re reserving access to a high-level, expert-informed strategic intelligence asset, built to help decision-makers navigate the next wave of opportunity and risk in CNS oncology, with a focus on glioblastoma and other high-need primary brain tumors.

Why You Can Trust This Report

  • Interviews with top neuro-oncologists, translational scientists, and CNS trialists
  • Built on a 10-question framework tailored to trial design, modality potential, and strategic bottlenecks
  • Exclusive pre-launch pricing for early supporters, with full refund flexibility

Global KOL Network, Strategic by Design

We’ve carefully selected 15+ KOLs to ensure diverse, relevant, and frontline insights , not just from major academic centers, but from key markets shaping the future of CNS development:

  • United States
  • United Kingdon
  • European Union
  • Brazil
  • China
  • Indonesia
  • Japan

This global scope is intentional , to provide insight into real-world practice patterns, feasibility, and regional innovation signals that matter for global strategy and BD.

What the Report Covers

Built around a 10-question KOL framework, this report is designed to extract real signal across five strategic domains:
1. Unmet Needs & Practice Reality
What’s broken, and what clinicians actually need
2. Pipeline & Modality Views
CAR-T, radiopharmaceuticals, TTFields, exosomes, ADCs what’s hype vs. hope?
3. Biomarkers & Stratification
Emerging tools for patient selection and response prediction
4. Trial Design Preferences
What would truly change practice? And what’s been consistently wrong?
5. Future Outlook & Big Bets
What KOLs are watching, and what they believe the industry must rethin

What You’ll Receive

• Synthesized analysis from 15+ expert interviews
• KOL themes, anonymized verbatims, and strategic takeaways
• Designed to support BD assessments, portfolio prioritization, platform validation, and clinical planning
• PDF + Executive Summary Slide Deck format
• Delivery: September 2025 (pre-orders receive it 30 days early)

Who It is for

  • Pharma BD & Strategy Executives exploring CNS opportunities 
  • Venture & PE Investors de-risking modality and pipeline bets
  • Biotech Leaders seeking clarity on differentiation and feasibility
  • R&D & Clinical Strategy Teams planning trials or new indications

Led by Dr. Fabio D’Agostino, an experienced biotech consultant with a background in science, venture capital, and strategic advisory, this initiative is supported by a global network with deep expertise in biotech venture, strategic consulting, and translational research. Together, we deliver clear, actionable insights to help CNS strategy teams navigate complexity with confidence.

 

Pricing and pre-order option

Standard Price = £ 5,950 + VAT (if applicable), Available post-launch 

Pre-order (Limited to First 10) = £3,950 + VAT (if applicable) Save over 30% + 30-day early access + full refund after executive summary review

Pre-Order Bonus – For the First 10 Buyers Only

1. Priority access to custom team add-ons (Pre-order customers will be first in line to request and receive tailored insights or extensions for their internal use.)
2.  Full refund after reviewing the executive summary (we know you’ll love it)
3. 30-day advance access to the full report (Secure the full report 30 days prior to its public release by placing a pre-order.)
4. Save over 30% off the standard post-launch price

Ready to Secure Strategic Advantage?

Pre-Order Now:  £3,950 +VAT (If applicable)
Fully refundable after reviewing the executive summary.
Only 10 early-access spots available.

To reserve your spot, simply email us and we’ll send next steps and an invoice if needed.

Have questions or need more details?

Contact us
Scroll to Top